|Home | About | Journals | Submit | Contact Us | Français|
In-stent restenosis and the need of repeat revascularisation remain the major limitations of coronary angioplasty for patients with multivessel disease.1,2 Utilisation of drug eluting stents in this context is expected to have a major impact on the effectiveness of percutaneous treatment. Sirolimus eluting stent implantation has recently been shown to significantly reduce coronary restenosis, with zero angiographic restenosis3,4 and persistent long term neointimal inhibition.4 Moreover, sirolimus eluting stents were proven to be as safe as bare metal stents at 30 days in a group of patients with acute coronary syndromes and a high frequency of multivessel disease.5 However, currently the effect of this device on long term outcomes of patients with multivessel disease is largely unknown.
The sirolimus eluting stent received Conformité Européenne mark approval in April 2002, since when it has been available for routine use in Europe. From 16 April 2002, it has been the policy of our institution to utilise sirolimus eluting stents as the device of choice for all percutaneous coronary interventions, as part of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital) study, which is a single centre registry conducted with the main purpose of evaluating the efficacy of sirolimus eluting stent implantation in the “real world”.5
In a preliminary analysis, the first 150 patients with multivessel disease included in the RESEARCH study were compared to a control group formed by 150 consecutive patients treated with bare stents in the period immediately before. Both groups were similar at baseline regarding the frequency of previous bypass surgery (19% v 18%, respectively; p = 1.0), three vessel disease (32% v 35%, respectively; p = 0.6), and diabetes (27% v 22%, respectively; p = 0.4). At six months follow up, the cumulative incidence of major adverse cardiac events (death, myocardial infarction, or repeat revascularisation) was significantly lower among those treated with sirolimus eluting stents (10.0% v 20.7% in controls; p = 0.01), mainly due to a pronounced reduction in the need for further revascularisation (3.3% v 12.7%; p = 0.003) (fig 11).). Although promising, however, these preliminary findings must be interpreted with caution until further confirmation with larger number of patients and more prolonged follow up is available.
Against the background of the impressive results of sirolimus eluting stent implantation in patients with single vessel disease and the promising initial findings of the RESEARCH study, the next ideal step should be a new randomised trial comparing treatment with multivessel stenting with the sirolimus eluting stent with the most advanced and up to date surgical treatment. However, before designing this new randomised trial it seems wise to improve the capabilities in treating complex multivessel disease (for example, main stem, total chronic occlusion, bifurcation, long lesion, small vessel). On the other hand, time is also needed in order to implement and vulgarise new surgical techniques that have been recently introduced and fully mastered in only certain centres of excellence. Therefore the ARTS II (arterial revascularisation therapies study part II) trial must be perceived as an intermediate phase towards the next full fledge second randomised ARTS trial.6
ARTS II is as a multicentre, non-randomised, open label, stratified trial designed to evaluate sirolimus eluting stent implantation in patients with multivessel disease using the surgical group of ARTS I as an historical control. To be comparable to the results of the ARTS I study, patients included in the ARTS II trial must present similar baseline characteristics. In order to ensure recruitment of a population very similar to the one of ARTS I, methodological techniques as “pseudo” randomisation or stratification will be applied.
The main goal of the ARTS II trial is to assess a non-inferiority of sirolimus eluting stent implantation for patients with multivessel disease with respect to the previous result of the surgical arm of the ARTS I trial.
The primary objective of ARTS II is to compare the effectiveness of coronary stent implantation using the sirolimus eluting Cypher (Cordis Johnson & Johnson, Warren, New Jersey, USA) balloon expandable stent with that of surgery as observed in ARTS I. Effectiveness is measured in terms of major cardiac and cerebrovascular events (MACCE)-free survival at one year:
The secondary objectives of this study are to compare the two groups with respect to:
In case of death its exact cause will be recorded whenever possible on the basis of a necropsy. All deaths are considered cardiac unless there is documentation to the contrary. Secondary analysis will look separately at cardiac and non-cardiac death.
Cerebrovascular events will be divided into three main categories: stroke, transient ischaemic attacks, and reversible ischaemic neurologic deficits.
All myocardial infarctions will be counted as events, whether they occurred spontaneously or in association with angioplasty or coronary artery bypass graft surgery procedures. A definite diagnosis of myocardial infarction is made:
Every subsequent revascularisation procedure is recorded, either percutaneous or surgical.
Direct medical cost—Resource use concerning the initial procedure, hospital admissions, and major diagnostic or therapeutic procedures after the initial procedure.
Quality of life—The patient’s quality of life will be assessed by the EuroQol and the SF-36 questionnaire (at randomisation, 30 days, six months, one year, three years, and five years). Furthermore, at the same point in time, the patient’s anginal status will be assessed by the Canadian Cardiovascular Society (CCS) classification and the Braunwald classification. Before the procedure, and at all planned follow up visits, patients will be asked to fill out a questionnaire concerning their work status.
A total of 600 eligible patients will be selected from the daily practices of 45–50 centres across Europe with a minimum enrolment of 12 eligible subjects per centre. Inclusion and exclusion criteria are presented in table 11.. Patients are stratified by clinical site in order to ensure inclusion of one third of three vessel disease versus two thirds of two vessel disease, as based on the patient population enrolled in ARTS I. An ongoing check on the success of matching with the historical control will be performed. If it appears that the population has less than 2.7 lesions, the recruitment scheme of “3-2-2” will be changed to “3-3-2”.
The sirolimus eluting Cypher balloon expandable stent is pre-mounted and crimped on the Raptor stent delivery system 5SDS. Direct stenting or pre-dilatation is left to the investigator’s discretion. In case of inadequate positioning (uncovered lesion), dissection or unmasking of a narrowing in the inflow or outflow area of the implanted stent, a second or third stent may be placed in series. Intravascular ultrasound or any other monitoring devices are allowed. A multi-staged procedure is allowed and should be declared either before the initial procedure or at the time the patient is leaving the interventional suite. Patients who do not have all diseased vessels dilated, but all targeted vessels are successfully dilated, will be classified as “incompletely revascularised by intent”. Those who do not have all targeted vessels successfully dilated will be classified as “incompletely revascularised, but not by intent”.
Clopidogrel (preferably) or ticlopidine for eight weeks (75 mg/day or 2 × 250 mg daily, respectively) and lifelong aspirin are commended. Clopidogrel (preferably) or ticlopidine should be used for at least six months for patients with diabetes or chronic total occlusion. Administration of glycoprotein IIb/IIIa inhibitors will only be considered in case of high instability, which cannot be controlled by any other means.
Due to the expected pronounced decrease in the need for repeat revascularisations, the incidence of MACCE after sirolimus eluting stent implantation is probably best estimated as the proportion of patients in ARTS with death/cerebrovascular accident/myocardial infarction (that is, 9.1% after pooling the data from both ARTS treatment arms). ARTS II will not consider surgery as a separate arm and therefore the uncertainty margins need to be defined in advance. The ARTS I trial suggests a point estimate of 87.8% with a 95% confidence interval of 83.4% to 92.3%. In order to reflect the additional uncertainties due to eventual (minimal) changes of surgery over the time since the recruitment of the ARTS trial and/or mismatches between the two trials with respect to patient characteristics, the variance will be inflated by 25%.
For the sample size calculations several approaches were taken into consideration, both concerning clinical and cost and cost effectiveness outcomes, using Bayesian and frequentist methodology. It was decided to take the comparative statistical methodology, using a mixture of Bayesian and frequentist methodology.
A sample size of 600 patients is chosen to guarantee a power of at least 90%. The sample size justification is based on the comparison of the ARTS I stented patients and the ARTS I surgery patients of the primary end point (one year MACCE). The null hypothesis is that the one year MACCE-free survival rate is at least as good as surgery minus 3.5%, being 84.3%. In the stented group an expected MACCE-free survival rate of 90.9% is used. This will be tested using a Bayesian approach.7 A one sided t test will be performed with a type I error rate of 0.05. Furthermore, an indication of the precision of the outcome of the ARTS II trial as a one arm registry is given as the width of the 95% two sided confidence intervals, being 4.8% (the 95% confidence interval around 90.9% is 88.3% to 93.1%).
Safety data of the 30 days, six months, one, three, and five years will be analysed; however, the formal Bayesian analysis of the primary objective will only be performed at one year. A final analysis on the safety data will be performed at five years.
Count variables will be given as group rates and their matching 95% confidence interval. Time-to-event variable will be presented as Kaplan-Meier curves. Continuous variables will be given as group means, and their matching 95% confidence intervals, and as the median, and the 10th and 90th centiles.
Distinction is made between the direct medical costs and the total costs including the indirect medical costs. Emphasis is placed on the direct medical costs that are calculated as the product of the vector of resource used with a vector of unit costs. The indirect non-medical costs are addressed in terms of days of absence from work. In terms of effects, distinction is made between event-free survival and quality adjusted life years gained (estimated using two indices). As a result, six estimates result of the cost effectiveness ratio and the uncertainty surrounding these six estimates will be addressed by the methodology as outlined by van Hout and colleagues.8
The primary analysis will be based on the intention-to-treat principle.
For the primary end point (MACCE at one year), comparing the ARTS II results with the historical controls of the ARTS trial, a Bayesian analysis will be used. Random and fixed effects will be pre-defined.
Analysis with respect to the cost effectiveness end points will be performed for the predefined subanalysis: two versus three vessel disease, age, and insulin dependent diabetes.
The ARTS II study, with enrolment started in early 2003 and rapidly proceeding, should provide evidence of the effects of percutaneous coronary intervention with sirolimus eluting stents for patients with multivessel disease, as compared to a historical control group composed of the surgical arm of the ARTS I trial. The ARTS II trial should thereby help to clarify the impact of the new strategy in this context. Nevertheless, it is clear that during this decade further assessment in respect of the values of these two modalities of revascularisation should be assessed in a major and maybe final randomised trial.